SecBot SecBot
DEFA14A ·Filed May 20, 2026

VXRT

Vaxart, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed6mo ago SEC0001213900-26-059239
Proxy solicitation materials
Actionable Insight • Neutral

The proxy fight is low-intensity given the dissident's small stake and the board's recent addition of a qualified independent director. The outcome likely favors management's slate. Monitor the annual meeting date and any further dissident filings for escalation.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.6100
T+0 close · May 20, 2026 · via day close
Latest settled
−10.90%
T+60 · $0.5435
Vs SPY
−15.91%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 20 $0.6100entry
  2. T+1 · 6mo ago +11.48%α +11.28% · $0.6800
  3. T+5 · 6mo ago +8.20%α +6.39% · $0.6600
  4. T+20 · 5mo ago −9.67%α −10.41% · $0.5510
  5. T+60 · 3mo ago −10.90%α −15.91% · $0.5435

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vaxart filed additional definitive proxy soliciting materials (DEFA14A) for its 2026 Annual Meeting, facing a contested director election from stockholder Daniel P. Houle, who nominated himself and two others. The filing identifies the board's six nominees and four executive officers as participants in the solicitation, reiterating the company's recommendation to vote FOR its slate. The dissident holds ~0.7% of shares, and the board recently added an independent director with biotech experience, strengthening its position.

Key Financial Metrics

Vote
director election
Seats Contested
3

Key Facts

  • Vaxart filed DEFA14A soliciting proxies for the 2026 Annual Meeting with a contested director election.
  • Stockholder Daniel P. Houle nominated himself and two others as dissident candidates.
  • The board unanimously recommends voting FOR its six nominees, citing the dissidents' lack of relevant biotech experience and small ownership stake (~0.7%).
  • The board recently appointed James B. Breitmeyer, M.D., Ph.D., a veteran biotech executive, as an independent director.
  • Participants in the solicitation include all six board nominees and four executive officers.

Financial Impact

No financial figures disclosed in the filing.

Risk Factors

  • Dissident could gain traction if institutional investors are dissatisfied with Vaxart's clinical progress or cash runway.
  • Proxy contest could distract management from pipeline execution.
  • Low probability of dissident slate winning given ownership disparity.

Market Snapshot

Exchange
OTC
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001213900-26-059239
Document: 0001213900-26-059239-index-headers.html0001213900-26-059239
Document: 0001213900-26-059239-index.html0001213900-26-059239
Document: 0001213900-26-059239.txt0001213900-26-059239

Track record

23 reports on VXRT

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +37.66% at T+60 after the May 1, 2026 report. 2 of 4 went positive at some point.

Filters
  1. Nov 5, 202611d ago 8-K Bearish 5/10 Entry $0.3700 Now $0.3600 +2.70% settles Feb 4
  2. Oct 19, 202628d ago 8-K Neutral 3/10 Entry $0.4900 Now $0.3600 −26.53% settles Jan 15
  3. Jul 28, 202615w ago 8-K Neutral 2/10 Entry $0.4800 to $0.4900 Now $0.3600 −25.00% ▲ +2.08% −2.53% vs SPY
  4. Jul 7, 202618w ago 8-K Neutral 4/10 Entry $0.5500 to $0.4500 Now $0.3600 −34.55% ▼ −18.18% −21.27% vs SPY
  5. Jul 6, 202619w ago DEFA14A Neutral 5/10 Entry $0.6200 to $0.4540 Now $0.3600 −41.94% ▼ −26.77% −28.93% vs SPY
  6. Jul 2, 202619w ago DEFA14A Bullish 5/10 Entry $0.6400 to $0.4500 Now $0.3600 −43.75% ▼ −29.69% −33.51% vs SPY
  7. Jul 2, 202619w ago 8-K Neutral 4/10 Entry $0.6400 to $0.4520 Now $0.3600 −43.75% ▼ −29.38% −32.80% vs SPY
  8. Jun 26, 202620w ago DEFA14A Neutral 4/10 Entry $0.5700 to $0.4900 Now $0.3600 −36.84% ▼ −14.04% −17.08% vs SPY
  9. Jun 26, 202620w ago DEFA14A Neutral 3/10 Entry $0.5700 to $0.4900 Now $0.3600 −36.84% ▼ −14.04% −17.08% vs SPY
  10. Jun 26, 202620w ago 8-K Mixed 5/10 Entry $0.5700 to $0.4900 Now $0.3600 −36.84% ▼ −14.04% −17.08% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 20, 2026